Here we will critically discuss the scientific rationale behind the use of PSMA-directed molecular imaging and therapeutics and compare it to other potential targets evaluated in imaging of metastatic prostate cancer to guide management. The gene discussed is FOLH1; the disease is prostate carcinoma.